Kiadis Pharma N.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kiadis Pharma N.V.
Kiadis Pharma’s CEO says its processed natural kill cell therapies can improve hematopoietic stem cell transplants and also treat resurgent leukemia.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Celmed BioSciences, Inc.
- Kiadis Pharma B.V.